Physician profile
Mara Young
NPI 1770359218
$3,456.85
in general payments reported to CMS, 2019-2025
21 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,008 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,456.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.98 | 2024-2025 | |
| Corcept Therapeutics | $522.57 | 2025 | Korlym |
| Novo Nordisk INC | $427.42 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $349.28 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $263.57 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.38 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $168.32 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.44 | 2024-2025 | Xifaxan |
| Alkermes, INC. | $106.31 | 2025 | Vivitrol |
| Lundbeck LLC | $92.68 | 2025 | Rexulti |
| Exact Sciences Corporation | $76.28 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $63.29 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $56.80 | 2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $52.20 | 2025 | Spravato |
| Glaxosmithkline, LLC. | $50.31 | 2024-2025 | Trelegy Ellipta, Arexvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36.40 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.24 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $22.78 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $22.28 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $22.07 | 2025 | |
| Phadia US INC. | $18.25 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.